logo-loader
viewOpen Orphan PLC

Open Orphan says hVIVO builds commercial momentum with £2.5mln influenza challenge study contract

It is working with an unnamed US biotechnology company

Open Orphan PLC -

Open Orphan PLC (LON:ORPH) said its hVIVO arm has won a £2.5mln contract to carry out an influenza human challenge study for an unnamed US biotechnology company.

The latest deal builds on significant new business wins in the areas of respiratory syncytial virus and coronavirus (COVID-19).

The challenge study will take place at the company’s 24-bedroom quarantine clinic in east London in the second half of next year with completion due by the end of 2021.

Open Orphan’s Venn Life Sciences Paris team will carry out the biometrics.

“Recent events have highlighted the importance of treatments for viral infections such as influenza and we are seeing an increased level of interest amongst both pharma and biotech in developing innovative new vaccines, antivirals, and therapeutics,” Open Orphan chairman Cathal Friel said in a statement.

Quick facts: Open Orphan PLC

Price: 25 GBX

AIM:ORPH
Market: AIM
Market Cap: £166.99 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Open Orphan present at the Proactive One2one virtual investment forum

Open Orphan PLC's (LON:ORPH) Cathal Friel presents at the Proactive One2One Virtual October Conference. The company's a rapidly growing specialist CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical...

1 week, 1 day ago

2 min read